MedElevator Войти в исследования
← Поиск публикаций

DOI 10.26355/eurrev_202403_35621

Медицинская библиотека · European review for medical and pharmacological sciences · 2024

A 3.5-year clinical experience with perampanel for refractory epilepsy.

Bin Teni T, Almutairi N A, Abuhaimed S, Alaskar S, Alkhamis G, Alsfouk B A, Almarzouqi M R, Alageel S, Alsemari A

СтатьяПеревод в очереди

Аннотация

OBJECTIVE

This study aimed to evaluate the efficacy and tolerability of perampanel, which was used in a cohort of patients with refractory epilepsy for up to 3.5 years in a real-world setting in Saudi Arabia.

PATIENTS AND

METHODS

Data from the medical records of patients treated with perampanel between March 13th, 2017, and September 6th, 2020, at neurology clinics at King Faisal Specialist Hospital and Research Centre (KFSHRC), Riyadh and Jeddah, Saudi Arabia, was collected. The Liverpool Adverse Events Profile (LAEP) scale was also used to measure the adverse effects of perampanel.

RESULTS

Of the 75 included patients, 66.7% responded to perampanel at the last follow-up, including 22.7% seizure-free for at least the last six months, and 44% of patients responded with a ≥ 50% reduction in seizure frequency from baseline. The overall incidence of adverse effects that led to perampanel discontinuation was 13.3%; the most common adverse effect was aggressive behavior followed by sedation. Pre-existing psychiatric comorbidity was significantly associated with the incidence of psychiatric and behavioral adverse effects on perampanel (p = 0.0206). The mean score of LEAP was 40. The most frequently rated adverse effects in LEAP were "feelings of anger and aggression to others", "nervousness and/or agitation" and "sleepiness". The efficacy and tolerability of perampanel were dose-dependent. Dose 6 mg/day was the most frequently used dose that was taken by about one-third of patients at their last visit.

CONCLUSIONS

Perampanel was effective as an adjunctive treatment for intractable seizures, with a responder rate of 66.7%. The long-term tolerability of perampanel was generally good. Aggressive behavior was the most common reason for perampanel discontinuation. Patients should be counseled and monitored for these adverse effects, particularly those with a history of previous psychiatric and behavioral problems.

Для цитирования: Bin Teni T, Almutairi N A, Abuhaimed S, Alaskar S, Alkhamis G, Alsfouk B A, Almarzouqi M R, Alageel S, Alsemari A. A 3.5-year clinical experience with perampanel for refractory epilepsy.. European review for medical and pharmacological sciences. 2024. DOI: 10.26355/eurrev_202403_35621.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.